Explore the words cloud of the FRAGNET project. It provides you a very rough idea of what is the project "FRAGNET" about.
The following table provides information about the project.
|Coordinator Country||Netherlands [NL]|
|Total cost||3˙842˙481 €|
|EC max contribution||3˙842˙481 € (100%)|
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
|Duration (year-month-day)||from 2016-03-01 to 2020-02-29|
Take a look of project's partnership.
|1||STICHTING VU||NL (AMSTERDAM)||coordinator||1˙021˙497.00|
|2||UNIVERSITY OF YORK||UK (YORK NORTH YORKSHIRE)||participant||819˙863.00|
|3||UNIVERSITAT DE BARCELONA||ES (BARCELONA)||participant||495˙745.00|
|4||TERMESZETTUDOMANYI KUTATOKOZPONT||HU (BUDAPEST)||participant||447˙827.00|
|5||VERNALIS (R&D) LIMITED||UK (CAMBRIDGE)||participant||273˙287.00|
|6||NOVARTIS PHARMA AG||CH (BASEL)||participant||265˙226.00|
|7||BEACTICA THERAPEUTICS AB||SE (UPPSALA)||participant||263˙659.00|
|8||ZOBIO BV||NL (LEIDEN)||participant||255˙374.00|
|9||24 Media Labs||NL (Rotterdam)||partner||0.00|
|10||F. HOFFMANN-LA ROCHE AG||CH (BASEL)||partner||0.00|
|11||GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.||UK (BRENTFORD)||partner||0.00|
|12||INSTITUT DE RECHERCHES SERVIER||FR (SURESNES)||partner||0.00|
|13||IOTA Pharmaceuticals Ltd||UK (CAMBRIDGE)||partner||0.00|
The promise of more efficient lead discovery is fuelling the enthusiasm for fragment-based lead discovery (FBLD). In this approach, highly sensitive biochemical and biophysical screening technologies are being used to detect the low affinity binding of low molecular weight compounds (the so-called fragments) to protein targets that are involved in pathophysiological processes. By investigating the molecular interactions between fragment hit(s) and the target protein, a detailed understanding of the binding event is obtained. This enables the rational and efficient optimisation of the hit fragment. The optimised compounds represent high quality leads for drug development. The necessary FBLD technologies and approaches have emerged mainly from small and specialised biotech companies. At present, FBLD is being adopted throughout pharmaceutical sciences, including by pharmaceutical companies, SMEs and academic research groups. So far, the necessary training that is needed to obtain an holistic view of the possibilities and opportunities that FBLD provides is missing, most likely because the highly multidisciplinary nature of the FBLD work is difficult to capture within one (academic) institute. Therefore, we have established FragNet as a dedicated FBLD training network. The consortium consists of the most prominent pharmaceutical companies, biotech companies and academic groups that have jointly shaped the FBLD research area. FragNet is committed to train 15 ESRs in all facets of FBLD using the combined technologies, skills and knowledge. This will include both research (e.g., technologies on the interface of chemistry and biology) and transferable skill sets (e.g., writing, media training, entrepreneurship and thorough understanding of scientific knowledge transfer). This will enable the ESRs to excel in today’s drug discovery and chemical biology programmes that are performed in public and private organisations in the pharmaceutical sciences.
|Open meetings organised||Other||2020-04-24 23:22:35|
|FragNet website||Websites, patent fillings, videos etc.||2020-04-09 09:21:05|
Take a look to the deliverables list in detail: detailed list of FRAGNET deliverables.
|year||authors and title||journal||last update|
Maciej Majewski, Sergio Ruiz-Carmona, Xavier Barril
An investigation of structural stability in protein-ligand complexes reveals the balance between order and disorder
published pages: , ISSN: 2399-3669, DOI: 10.1038/s42004-019-0205-5
|Communications Chemistry 2/1||2020-04-09|
Moira M Rachman, Xavier Barril, Roderick E Hubbard
Predicting how drug molecules bind to their protein targets
published pages: 34-39, ISSN: 1471-4892, DOI: 10.1016/j.coph.2018.07.001
|Current Opinion in Pharmacology 42||2020-04-09|
PÃ©ter ÃbrÃ¡nyi-Balogh, LÃ¡szlÃ³ Petri, TÃmea Imre, PÃ©ter Szijj, Andrea Scarpino, Martina Hrast, Ana MitroviÄ‡, UrÅ¡a PeÄar FonoviÄ, Krisztina NÃ©meth, HÃ©lÃ¨ne Barreteau, David I. Roper, Kata HorvÃ¡ti, GyÃ¶rgy G. Ferenczy, Janko Kos, Janez IlaÅ¡, Stanislav Gobec, GyÃ¶rgy M. KeserÅ±
A road map for prioritizing warheads for cysteine targeting covalent inhibitors
published pages: 94-107, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2018.10.010
|European Journal of Medicinal Chemistry 160||2020-04-09|
Angelo K.S. Romasanta, Peter van der Sijde, Iina Hellsten, Roderick E. Hubbard, Gyorgy M. Keseru, Jacqueline van Muijlwijk-Koezen, Iwan J.P. de Esch
When fragments link: a bibliometric perspective on the development of fragment-based drug discovery
published pages: 1596-1609, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2018.05.004
|Drug Discovery Today 23/9||2020-04-09|
Scarpino, Bajusz, Proj, Gobec, SosiÄ, Gobec, Ferenczy, KeserÅ±
Discovery of Immunoproteasome Inhibitors Using Large-Scale Covalent Virtual Screening
published pages: 2590, ISSN: 1420-3049, DOI: 10.3390/molecules24142590
Andrea Scarpino, GyÃ¶rgy G. Ferenczy, GyÃ¶rgy M. KeserÅ±
Comparative Evaluation of Covalent Docking Tools
published pages: 1441-1458, ISSN: 1549-9596, DOI: 10.1021/acs.jcim.8b00228
|Journal of Chemical Information and Modeling 58/7||2020-04-09|
Aaron Keeley, PÃ©ter ÃbrÃ¡nyi-Balogh, Martina Hrast, TÃmea Imre, Janez IlaÅ¡, Stanislav Gobec, GyÃ¶rgy M. KeserÅ±
Heterocyclic electrophiles as new MurA inhibitors
published pages: 1800184, ISSN: 0365-6233, DOI: 10.1002/ardp.201800184
|Archiv der Pharmazie 351/12||2020-04-09|
Bas Lamoree, Roderick E. Hubbard
Using Fragment-Based Approaches to Discover New Antibiotics
published pages: 495-510, ISSN: 2472-5552, DOI: 10.1177/2472555218773034
|SLAS DISCOVERY: Advancing the Science of Drug Discovery 23/6||2020-04-09|
Moira Rachman, Andrea Scarpino, DÃ¡vid Bajusz, Gyula PÃ¡lfy, IstvÃ¡n Vida, AndrÃ¡s Perczel, Xavier Barril, GyÃ¶rgy M. KeserÅ±
DUckCov: a Dynamic Undockingâ€Based Virtual Screening Protocol for Covalent Binders
published pages: 1011-1021, ISSN: 1860-7179, DOI: 10.1002/cmdc.201900078
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FRAGNET" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "FRAGNET" are provided by the European Opendata Portal: CORDIS opendata.
Creating Granular Materials Experts by Developing Experimental Calibrations for Computational MethodsRead More
INtegrating Functional Assessment measures for Neonatal SafeguardRead More
Synthetic biology of carbohydrate-binding proteins: engineering protein-carbohydrate interactions for diagnostics and cell targetingRead More